KIT and gastric cancer: To our knowledge, apatinib inhibited VEGFR-2, PDGFR-β, SRC, c-KIT, and RET [26], demonstrating positive clinical outcomes for metastatic GC with ORR of 2.84%, DCR of 42.05%, and median PFS of 2.6 months [13].